TGTX - TG Therapeutics, Inc.
6.47 0.00 (0.00%)
After hours: 4:36PM EDT
| Previous Close | 6.58 |
| Open | 6.56 |
| Bid | 6.44 x 1000 |
| Ask | 6.48 x 3000 |
| Day's Range | 6.44 - 6.66 |
| 52 Week Range | 3.32 - 9.49 |
| Volume | 560,101 |
| Avg. Volume | 1,263,271 |
| Market Cap | 613.066M |
| Beta (3Y Monthly) | 2.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.96 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
- Simply Wall St.
Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
- Benzinga
The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 11.) Avedro Inc (NASDAQ: AVDR ) Catalyst Pharmaceuticals ...
- GlobeNewswire
TG Therapeutics Presents Data for Ublituximab at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
TG Therapeutics, Inc. (TGTX), today presented the first look at the ULTIMATE I & II Phase 3 trial design and demographic data and updated Phase 2 extension trial data for ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS) at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held in Stockholm, Sweden. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, “We are pleased to present the first look at the study design and patient demographics data from our Phase 3 ULTIMATE program.
- GlobeNewswire
TG Therapeutics Announces Data Presentations at the Upcoming 35th Annual Congress of ECTRIMS
TG Therapeutics, Inc. (TGTX), today announced that abstracts featuring ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS) have been accepted for presentation at the upcoming 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), to be held September 11 – 13, 2019 in Stockholm, Sweden. Abstracts are now available online and can be accessed on the ECTRIMS meeting website at www.ectrims-congress.eu.
- GlobeNewswire
TG Therapeutics Mourns the Loss of Board Member, Mark Schoenebaum, MD
NEW YORK, Aug. 26, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX) announced with great sadness the passing of longtime Board Member, Mark Schoenebaum, MD. "Everyone at TG is.
- Thomson Reuters StreetEvents
Edited Transcript of TGTX earnings conference call or presentation 9-Aug-19 12:30pm GMT
Q2 2019 TG Therapeutics Inc Earnings Call
- Benzinga
Large Option Trader Sells TG Therapeutics Calls After Big Run
On Monday morning, Benzinga Pro subscribers received an option alert due to an unusually large TG Therapeutics trade. Due to the relatively complex nature of the options market, options traders are generally considered to be more sophisticated than the average stock trader. In addition, large options traders are often professional, wealthy individuals or institutions, either of which could have unique insight or information about a company.
- Simply Wall St.
What Kind Of Shareholder Owns Most TG Therapeutics, Inc. (NASDAQ:TGTX) Stock?
A look at the shareholders of TG Therapeutics, Inc. (NASDAQ:TGTX) can tell us which group is most powerful. Generally...
Motley FoolTG Therapeutics Inc (TGTX) Q2 2019 Earnings Call Transcript
TGTX earnings call for the period ending June 30, 2019.
- GlobeNewswire
TG Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results
NEW YORK, Aug. 09, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2019 and recent company.
- GlobeNewswire
TG Therapeutics to Host Conference Call on Second Quarter 2019 Financial Results and Business Update
NEW YORK, Aug. 07, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Friday, August 9, 2019 at 8:30 AM ET to discuss results.
- GuruFocus.com
Steven Cohen Charges Into Chiasma
Guru invests in clinical-stage biopharmaceutical company Continue reading...
- Thomson Reuters StreetEvents
Edited Transcript of TGTX earnings conference call or presentation 10-May-19 12:00pm GMT
Q1 2019 TG Therapeutics Inc Earnings Call
- Insider Monkey
Here’s What Hedge Fund Think About TG Therapeutics Inc (TGTX)
How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
- GlobeNewswire
TG Therapeutics Announces Presentation of Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis During an Oral Session at the 5th Congress of the European Academy of Neurology
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases, today announced the presentation of long-term follow-up data from the Phase 2 and Open Label Extension (OLE) trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS).
- GuruFocus.com
Weekly CEO Buys Highlight
Details the CEO buys this past week for the following companies: Odonate Therapeutics, Carnival PLC, TG Therapeutics, Liberty Latin America and Biohaven
- Simply Wall St.
Is TG Therapeutics, Inc.'s (NASDAQ:TGTX) Balance Sheet Strong Enough To Weather A Storm?
While small-cap stocks, such as TG Therapeutics, Inc. (NASDAQ:TGTX) with its market cap of US$595m, are popular for...
- GlobeNewswire
TG Therapeutics to Present at the Raymond James Life Sciences and MedTech Conference
NEW YORK, June 18, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will.
- GlobeNewswire
TG Therapeutics Presents Preclinical Data for TG-1801, a First-in-Class Anti-CD47/CD19 Bispecific Antibody, at the 24th European Hematology Association Annual Congress
TG Therapeutics, Inc. (TGTX) today announced the presentation of preclinical data for TG-1801, the Company’s first-in-class anti-CD47/CD19 bispecific antibody, highlighting the synergistic effect of TG-1801 in combination with ublituximab, the Company’s anti-CD20 monoclonal antibody and umbralisib, the Company’s PI3K-delta inhibitor.
- GlobeNewswire
TG Therapeutics Confirms Registration Path for Umbralisib in Marginal Zone Lymphoma Following FDA Meeting
TG Therapeutics, Inc. (TGTX), today announced that the Company has confirmed its path to submit umbralisib for accelerated approval based on data from the marginal zone lymphoma (MZL) cohort of the UNITY-NHL Phase 2b trial. The Company recently had a productive Breakthrough Therapy Designation (BTD) meeting with the U.S. Food and Drug Administration (FDA) to discuss the MZL submission strategy.
- GlobeNewswire
TG Therapeutics Presents Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 55th American Society of Clinical Oncology (ASCO) Annual Meeting
TG Therapeutics, Inc. (TGTX) today presented positive interim data from the ongoing single-arm marginal zone lymphoma (MZL) cohort of its Phase 2b UNITY-NHL trial currently evaluating umbralisib as a single agent in patients with relapsed/refractory MZL. Umbralisib is an investigational, oral, once-daily PI3K delta inhibitor with unique inhibition of CK1 epsilon and is currently under development for the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
- GlobeNewswire
TG Therapeutics to Present at the Jefferies 2019 Healthcare Conference
Presentation scheduled for tomorrow, Wednesday, June 5, 2019, at 9:00 AM ET NEW YORK, June 04, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S..
- TheStreet.com
TG Therapeutics May Have Potential but the Charts Need More Work
For his "Executive Decision" segment of Mad Money Thursday night, Jim Cramer sat down with Michael Weiss, chairman, president and CEO of TG Therapeutics Inc. Cramer noted that TGTX is a speculative company, one that still has no revenues, but their story continues to be compelling. In the daily bar chart of TGTX, below, we can see what looks like a base pattern to me when we look at volume along with the price action.
- CNBC Videos
TG Therapeutics CEO: Going through the process to reach big markets
Jim Cramer catches up with TG Therapeutics CEO Michael Weiss in the wake of its latest earnings report.
